DICLOFENAC MISOPROSTOL TABLET (ENTERIC-COATED)

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

DICLOFENAC SODIUM; MISOPROSTOL

Доступна с:

ABRI PHARMACEUTICALS INC

код АТС:

M01AB55

ИНН (Международная Имя):

DICLOFENAC, COMBINATIONS

дозировка:

75MG; 200MCG

Фармацевтическая форма:

TABLET (ENTERIC-COATED)

состав:

DICLOFENAC SODIUM 75MG; MISOPROSTOL 200MCG

Администрация маршрут:

ORAL

Штук в упаковке:

100/250/500

Тип рецепта:

Prescription

Терапевтические области:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0222885004; AHFS:

Статус Авторизация:

CANCELLED PRE MARKET

Дата Авторизация:

2017-09-12

Характеристики продукта

_ _
_ _
_Page 1 of 48_
PRODUCT MONOGRAPH
_PR_
DICLOFENAC MISOPROSTOL
Diclofenac sodium and Misoprostol Enteric-coated Tablets
50 mg diclofenac/200 µg misoprostol
and
75 mg diclofenac/ 200 µg misoprostol
NSAID with a
Mucosal Protective Agent
Abri Pharmaceuticals Inc.
6500 Kitimat Road
Mississauga, ON
Canada, L5N 2B8
Date of Preparation:
April 18, 2013
Submission Control No: 163906
_ _
_ _
_Page 2 of 48_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
15
DRUG INTERACTIONS
.................................................................................................
19
DOSAGE AND ADMINISTRATION
.............................................................................
22
OVERDOSAGE
...............................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 24
STORAGE AND STABILITY
.........................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 26
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
PHARMACEUTICAL INFORMATION
.........................................................................
28
CLINICAL TRIALS
................................................................................